-
Mashup Score: 5Regeneron: Forging Our Future Through Scientific Innovation - 17 day(s) ago
Learn more about Regeneron’s mission to use the power of science to repeatedly bring new medicines to patients… over and over again.
Source: yearinreview.regeneron.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 13
Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment from Regeneron at signing TARRYTOWN,
Source: investor.regeneron.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 13
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo ® (cemiplimab-rwlc) 17 presentations to highlight Regeneron ‘s investigational
Source: investor.regeneron.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 82024 AAD Annual Meeting - 2 month(s) ago
The 2024 AAD Annual Meeting is scheduled to take place March 8-12 in San Diego, California. Expand your expertise through hundreds of expert-led sessions and make lasting connections with your peers.
Source: www.aad.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 8Regeneron Pharmaceuticals: Delivering Life-transforming Medicines - 5 month(s) ago
Regeneron (NASDAQ: REGN) is a leading biotechnology company using the power of science to bring new medicines to patients in need. Learn more.
Source: www.regeneron.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 30
NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL), confirming results from the
Source: investor.regeneron.comCategories: General Medicine News, PayerTweet-
#BREAKING: Our mission is to always push the boundaries of science to help people with serious diseases. And with @Sanofi, we’re doing just that for those living with moderate-to-severe #COPD. Read more about today’s news and what it may mean for patients: https://t.co/7ew9lUhD7p https://t.co/GPomSDAHK0
-
-
Mashup Score: 24
Regeneron has sponsored ISEF – the world’s largest high school science and engineering competition, and a program of Society for Science (Society) – since 2019 Each year, over 175,000 students participate in the Society’s affiliated high school science fairs around the world to earn the right to
Source: investor.regeneron.comCategories: General Medicine News, PayerTweet
2023 was a big year for us. What made it so special? Hear our co-Founders, Len Schleifer and George Yancopoulos, reflect on our progress, and explore more in our Year in Review (for investor audiences): https://t.co/niGjHQWuOJ https://t.co/rdqPr9Ewjt